GlassScriptPhysician profile
Timothy Michael Koehler
NPI 1871596684
$4,661.90
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $858 · 2021: $988 · 2022: $950.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,517.03 | 2019-2022 | |
| Novo Nordisk INC | $989.91 | 2019-2022 | |
| Abbvie INC. | $467.10 | 2020-2022 | |
| Amgen INC. | $264.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $149.15 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $132.66 | 2020-2022 | |
| Lilly USA, LLC | $121.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $117.47 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.64 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $98.82 | 2020 | |
| Abbott Laboratories | $92.23 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.31 | 2019-2022 | |
| Eisai INC. | $83.06 | 2020 | |
| Esperion Therapeutics, INC. | $74.50 | 2021 | |
| Astellas Pharma US INC | $62.12 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $41.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.04 | 2022 | |
| Tris Pharma INC | $25.72 | 2019 | |
| Allergan, INC. | $24.70 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.70 | 2020 | |
| Amarin Pharma, INC. | $16.52 | 2020 | |
| Glaxosmithkline, LLC. | $16.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.76 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$5,690.55 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.